Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32691024
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
COVID-19 and Myocarditis: What Do We Know So Far?
#MMPMID32691024
Pirzada A
; Mokhtar AT
; Moeller AD
CJC Open
2020[Jul]; 2
(4
): 278-285
PMID32691024
show ga
COVID-19 has been declared a global pandemic by the World Health Organization and
is responsible for hundreds of thousands of deaths worldwide. COVID-19 is caused
by SARS-CoV-2, and common clinical symptoms include fever, cough, sore throat,
headache, and fatigue. Myocardial injury is relatively common in patients with
COVID-19, accounting for 7%-23% of cases, and is associated with a higher rate of
morbidity and mortality. There is a discrepancy in the literature about
myocarditis as the etiology of myocardial injury in patients with COVID-19;
although many anecdotal reports of myocarditis have been noted, there are only a
handful of case reports in the literature about myocarditis related to COVID-19.
In this review we summarize the most up to date literature around the association
between COVID-19 and myocarditis and provide clinicians a practical framework
about the clinical manifestations, diagnostic tools, and treatment options
currently available. Importantly, this review will heighten suspicion for
myocarditis as an etiology of myocardial injury in COVID-19 patients, therefore
improving clinical outcomes and encouraging shared clinical decision-making. This
will also open the door for further research to build around this review.
Emergent treatment options for COVID-19 are in clinical trials and might be of
benefit to COVID-19 patients with myocarditis in addition to current
guideline-based recommendations.
free
free
free
